BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND P2RY8, RP11-261P4_4, 286530, ENSG00000182162, MGC50878, P2Y8, Q86VZ1
23944 results:

  • 1. Interleukin 33 supports squamous cell carcinoma growth via a dual effect on tumour proliferation, migration and invasion, and T cell activation.
    Perri G; Vilas Boas VG; Nogueira MRS; Mello Júnior EJF; Coelho AL; Posadas EM; Hogaboam C; Cavassani KA; Campanelli AP
    Cancer Immunol Immunother; 2024 Apr; 73(6):110. PubMed ID: 38662248
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Exceptional lymph node recurrence of an unusual ovarian tumor 16 years later: a case report.
    Sakhri S; Slimane M; Bouaziz H; Khessairi N; Boujelbene N; Ben Dhiab T
    J Med Case Rep; 2024 Apr; 18(1):217. PubMed ID: 38654310
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Granulosa cell tumor of the ovary: a series of 6 cases.
    da Costa REAR; Silva MCA; Cavalcante ECX; Branco ROC; Dos Reis CA; Vieira SC
    Pan Afr Med J; 2024; 47():58. PubMed ID: 38646138
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
    Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer.
    Guo J; Zeng X; Zhu Y; Yang D; Zhao X
    J Transl Med; 2024 Apr; 22(1):367. PubMed ID: 38637885
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant ovarian cancer: Final Overall Survival and Biomarker Analyses.
    Konstantinopoulos PA; Cheng SC; Lee EK; da Costa AABA; Gulhan D; Wahner Hendrickson AE; Kochupurakkal B; Kolin DL; Kohn EC; Liu JF; Penson RT; Stover EH; Curtis J; Sawyer H; Polak M; Chowdhury D; D'Andrea AD; Färkkilä A; Shapiro GI; Matulonis UA
    JCO Precis Oncol; 2024 Apr; 8():e2300635. PubMed ID: 38635934
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Imaging for local recurrence of breast cancer.
    Schlaiss T; Bott L; Herbert SL; Bartmann C; Kiesel M; Salmen J; Sauer ST; Christner SA; Petritsch B; Grunz JP; Woeckel A; Löb S; Diessner J
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):200. PubMed ID: 38627285
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants.
    Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
    Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [Gonadoblastoma: Clinicopathological study and literature review of 3 cases].
    Bao ML; Li X; Chen G; Li H; Chen W; Li HX
    Zhonghua Nan Ke Xue; 2023 Jul; 29(7):634-638. PubMed ID: 38619412
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Cytotoxic activity and cell specificity of a novel LHRH peptide drug conjugate, D-Cys6-LHRH vedotin, against ovarian cancer cell lines.
    Vankadara S; Ke Z; Wang S; Foo SY; Gunaratne J; Lee MA; Koh X; Chia CSB
    Chem Biol Drug Des; 2024 Apr; 103(4):e14516. PubMed ID: 38618710
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The Clinicopathological Significance of the Cyclin D1/E1-Cyclin-Dependent Kinase (CDK2/4/6)-Retinoblastoma (RB1/pRB1) Pathway in Epithelial ovarian cancers.
    Lashen A; Algethami M; Alqahtani S; Shoqafi A; Sheha A; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612869
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Common misconceptions and myths about ovarian cancer causation: a national cross-sectional study from palestine.
    Elshami M; Jaber I; Alser M; Al-Slaibi I; Jabr H; Ubaiat S; Tuffaha A; Khader S; Khraishi R; Arafeh ZA; Al-Madhoun S; Alqattaa A; Yaseen A; El Hadi AA; Barhoush O; Hijazy M; Eleyan T; Alser A; Hziema AA; Shatat A; Almakhtoob F; Mohamad B; Farhat W; Abuamra Y; Mousa H; Adawi R; Musallam A; Albarqi SI; Abu-El-Noor N; Bottcher B
    BMC Public Health; 2024 Apr; 24(1):1027. PubMed ID: 38609950
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Construction and analysis of competitive endogenous RNA networks and prognostic models associated with ovarian cancer based on the exoRBase database.
    Chen Z; Wang C; Ding J; Yu T; Li N; Ye C
    PLoS One; 2024; 19(4):e0291149. PubMed ID: 38603733
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses.
    Baik SH; Baye F; McDonald CJ
    Menopause; 2024 May; 31(5):363-371. PubMed ID: 38595196
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Development and validation of an ultrasound-based deep learning radiomics nomogram for predicting the malignant risk of ovarian tumours.
    Du Y; Xiao Y; Guo W; Yao J; Lan T; Li S; Wen H; Zhu W; He G; Zheng H; Chen H
    Biomed Eng Online; 2024 Apr; 23(1):41. PubMed ID: 38594729
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Olaparib Addition to Maintenance Bevacizumab Therapy in ovarian Carcinoma With BRCA-Like Genomic Aberrations.
    Schouten PC; Schmidt S; Becker K; Thiele H; Nürnberg P; Richters L; Ernst C; Treilleux I; Medioni J; Heitz F; Pisano C; Garcia Y; Petru E; Hietanen S; Colombo N; Vergote I; Nagao S; Linn SC; Pujade-Lauraine E; Ray-Coquard I; Harter P; Hahnen E; Schmutzler RK
    JAMA Netw Open; 2024 Apr; 7(4):e245552. PubMed ID: 38592722
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
    Mehra T; Lupatsch JE; Kössler T; Dedes K; Siebenhüner AR; von Moos R; Wicki A; Schwenkglenks ME
    PLoS One; 2024; 19(4):e0301271. PubMed ID: 38573891
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Mitogen-Activated Protein Kinase Inhibitor-Induced Inflammatory Alopecia in Woman With ovarian cancer.
    Rose L; Minta A; Plaza J; Cohn DE; Dulmage B
    J Drugs Dermatol; 2024 Apr; 23(4):e102-e103. PubMed ID: 38564383
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.
    Yuan H; Li N; Wu L; Yao H
    J Ovarian Res; 2024 Apr; 17(1):70. PubMed ID: 38561819
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. [Non-primary solid malignancies of breast in needle core biopsy: a clinicopathological analysis of 23 cases].
    Gu WQ; Wang L; Xu JC; Ping GQ; Han X; Wang C
    Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):331-336. PubMed ID: 38556815
    [No Abstract]    [Full Text] [Related]  


    [Next]

    of 1198.